BioSpace News Archive

Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the first quarter 2023 on Wednesday, May 3 at 9 a.m., ET.

Galera Therapeutics, Inc. (Nasdaq: GRTX) today announced that a prespecified analysis from the Phase 3 ROMAN trial detailing one-year reductions in cisplatin-related chronic kidney disease in patients with head and neck cancer treated with avasopasem will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Affimed N.V. announced that two abstracts with its innate cell engager AFM24 have been accepted for the American Society of Clinical Oncology Annual Meeting, taking place June 2 - 6, 2023 in Chicago, IL.

Bolt Biotherapeutics, Inc. announced that it will present a poster with clinical data from its completed Phase 1 dose-escalation study of BDC-1001 at the 2023 American Society for Clinical Oncology Annual Meeting.

Immutep Limited today announces two abstracts have been selected for poster presentation at the upcoming 2023 American Society of Clinical Oncology’s (ASCO) Annual Meeting, taking place in-person and online from 2-6 June 2023 in Chicago, Illinois (United States).

IN8bio, Inc. today announced an oral presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago from June 2-6, 2023.

Zentalis ® Pharmaceuticals, Inc. announced today that it will present positive clinical data from its Phase 1b trial investigating azenosertib in combination with chemotherapy in patients with advanced platinum-resistant ovarian cancer in a poster at the American Society of Clinical Oncology (ASCO) Meeting in Chicago, June 2-6, 2023.

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the acceptance of clinical abstracts for multiple programs across its precision therapy portfolio at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2 to 6.

Theseus Pharmaceuticals, Inc. today announced that initial dose escalation data from the ongoing phase 1/2 study of THE-630 in advanced gastrointestinal stromal tumors (GIST) were accepted for online publication at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, in Chicago, Illinois.

Covalon Technologies Ltd., an advanced medical technologies company, announced its attendance at the 48th Annual Canadian Vascular Access Association Conference and World Congress on Vascular Access Special Event from Wednesday, April 26 to Friday, April 28, 2023 in Toronto, Canada.